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oDITORIAL COMMENT
ranscatheter Valve Replacement:
New Era of Percutaneous
ardiac Intervention Begins*
iyad M. Hijazi, MD, MPH, FACC
hicago, Illinois
etralogy of Fallot with or without pulmonary atresia
ccounts for approximately 10% of all forms of congenital
eart disease. Establishing unobstructed blood flow between
he right ventricle (RV) and the confluence of the pulmo-
ary arteries using the transannular patch technique or via
he insertion of an interposition graft valve between the RV
nd pulmonary artery have been the main surgical options
or such defects. Such operations are associated with long-
erm complications, including pulmonary insufficiency with
ts sequelae on the RV, and pulmonary stenosis, resulting in
V hypertension and arrhythmias requiring graft valve
eplacement (1). Operations to replace or insert grafts are
ssociated with certain mortality and morbidity. However,
esurrecting the pulmonary valve is associated with im-
roved RV function, functional class, and atrial arrhythmias
2). Homograft or porcine valve placement in infants and
hildren require replacement because of graft degeneration
See page 1082
nd growth of the child. Depending on the type of valve in
he pulmonary position, two to four surgeries are required to
eplace such grafts in a lifetime of a child (3–5). Therefore,
nonsurgical option to resurrect the pulmonary valve and to
liminate pulmonary insufficiency and or stenosis will be
elcomed by both patients and their families. Such a
rocess would require a safe technique for the replacement
nd a valve that may last for many years.
The technique that will be adopted by the majority of
ardiologists has to be safe with very low risk of mortality
nd morbidity and should be easy to perform even in smaller
hildren. The valve to be inserted has to be ideal, meeting
ertain characteristics (wish list), including that is biocom-
atible with no long-term morbidity; should last preferably
or a lifetime, but at least 7 to 10 years before its degener-
tion; expandable to accommodate growth of the child; can
ccommodate a large right ventricle outflow tract; requires
mall delivery system; if it malfunctions, does not lead to a
atastrophe; and last but not least, economical. Further-
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Section of Pediatric Cardiology, Department of Pediatrics, University ofshicago Children’s Hospital and the Pritzker School of Medicine, Chicago, Illinois.ore, the operator should have full control of the prosthesis
ith the ability to adjust position before its full deployment.
Bonhoeffer et al. (6,7) reported on the first experimental
nd initial clinical human application of a percutaneous
alve in the pulmonic position. The prosthesis they used was
ade of a balloon-expandable stent with a bovine jugular
alve. The major limitations of that valve assembly were the
ize of the delivery sheath required (18F), rendering the
pplication in smaller children very difficult, if not impos-
ible, and the size of the valve available (up to 18 mm),
endering the application limited to homografts18 mm in
iameter. This size may not be adequate for an adult
atient, especially if one takes into consideration that the
ative valve is not removed in the process, creating further
arrowing in the valve (8). However, this valve assembly will
ertainly eliminate or reduce the number of operations
eeded in a lifetime of a patient with pulmonary insuffi-
iency/stenosis due to graft dysfunction. All patients who
eceived this valve in the pulmonary position had either a
ynthetic graft or a homograft with a diameter that does not
xceed 22 mm (Dr. P. Bonhoeffer, personal communication,
003). Therefore, it was relatively easy to secure the
alloon-expandable valve in that position. However, a large
umber of patients after tetralogy of Fallot repair have
ndergone the transannular patch repair technique. This
echnique of repair results in significant enlargement of the
V outflow tract with aneurysmal dilation rendering place-
ent of any stented valve 25 mm in diameter to be very
ifficult if not impossible.
During surgical valve replacement (synthetic or biologi-
al) in such patients with large RV outflow tract, the
urgeon usually reduces the size of the outflow tract and
laces a valve in that position. However, such operations are
ssociated with morbidity and mortality. Therefore, a per-
utaneous technique of RV outflow tract reduction and
lacement of a valve will broaden the scope of this technique
nd will render the majority of patients with pulmonary
nsufficiency/stenosis eligible for percutaneous valve replace-
ent.
In this issue of the Journal, Boudjemline et al. (9) report
n a novel technique of percutaneous reduction of the RV
utflow tract in an animal model. They described two
echniques of achieving the reduction and placement of the
alve: in one group of animals, the authors created a covered
elf-expandable stent with a restricted diameter in the
iddle of 18 mm and 15 mm in length and proximal and
istal ends of 30 mm in diameter to assure fixation of this
tent to the outflow tract and the distal main pulmonary
rtery. The venous valve segment was sewn in the middle of
he restricted part. The authors implanted the entire assem-
ly in these animals and achieved very good valve function
ith good results. In the other group, the valve insertion was
one in two steps. The first step was to reduce the RV
utflow tract by implanting the covered self-expandable
tent by itself; this was followed 6 to 10 weeks later by
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March 17, 2004:1088–9 Editorial Commentmplanting the stented valve (bovine jugular vein valve)
sing similar technique to what they have reported previ-
usly (6–8). There are obvious advantages and disadvan-
ages to each technique. The first technique can be per-
ormed in one procedure, thus eliminating a second
rocedure; however, the delivery system requires a large
heath, rendering its application in smaller children very
ifficult. The second technique, however, requires two
atheter procedures with the inherent technical difficulties
et when trying to cross the stent that was implanted
reviously. However, the delivery sheaths required are
maller and hence increase the number of small children
ligible for the valve.
I believe the first technique will be the one that operators
hoose the most. Miniaturization of equipment used (bal-
oon catheters, stents) will certainly render this technique
pplicable in the treatment of patients with pulmonary
nsufficiency/stenosis after surgical repair of tetralogy of
allot.
The valve used in the study was harvested from the
ovine jugular vein. However, one needs to know that data
re still missing on the mid- and long-term results of this
alve in humans. If this valve proves to be as good as
omografts or porcine valves, then I am certain that it will
e applied in more patients needing competent valve. This
ew era of percutaneous cardiac intervention will open the
oor for thousands of patients to benefit from this technol-
gy. Clinical trials will commence in the very near future in
he U.S. to assess the safety and effectiveness of such
ercutaneous valves for children post-tetralogy of Fallot
epair.
Interest in percutaneous valves has sparked few compa-
ies to design and develop percutaneous aortic and pul-
onic valves. Already after the first successful human case
eport of a percutaneous aortic valve (10), many companies
re developing percutaneous aortic and pulmonic valves. I
m aware of the following companies that are currently
ngaged in percutaneous aortic and or pulmonic valve
evelopment: 1) Percutaneous Valve Technologies, who
lready have a balloon-expandable aortic valve stent made of
quine pericardium and stainless steel. Nine patients (at the
ime of writing this editorial) have received this valve. 2)
edtronic Corporation/NuMED Inc., and their balloon-
xpandable valve stent (6–8) composed of bovine jugular
ein and platinum/iridium and designed for the pulmonic
osition. Twenty-eight patients received this valve. 3) Core
alve’s self-expandable valve made of tissue and nitinol
esigned for the aortic valve. 4) Shelhigh Inc.’s self-xpandable valve made of porcine valve and nitinol and
esigned for the pulmonic position. 5) Cook Inc.’s self-
xpandable valve made of small intestinal submucosa of pigs
nd nitinol and designed for the pulmonic position. And 6)
almaz/Bailey’s self-expandable valve made of nitinol mem-
rane and nitinol stent. It is designed for the aortic valve.
here are few other companies that are designing valves but
re still at the very early stages of development.
This is very exciting era for percutaneous cardiac inter-
ention. If such valves and procedures are proved safe and
ffective, hundreds of thousands of patients with calcific
ortic stenosis and thousands of patients with pulmonic
nsufficiency may benefit from this exciting new technology
nd certainly mark a new era for the interventional cardiol-
gist.
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